BidaskClub upgraded shares of Fluidigm (NASDAQ:FLDM) from a hold rating to a buy rating in a research report report published on Tuesday.

Several other brokerages have also recently commented on FLDM. Zacks Investment Research upgraded shares of Fluidigm from a sell rating to a hold rating in a report on Thursday, September 20th. Piper Jaffray Companies upgraded shares of Fluidigm from a neutral rating to an overweight rating in a report on Friday, November 2nd.

Shares of FLDM opened at $8.30 on Tuesday. Fluidigm has a 12 month low of $4.65 and a 12 month high of $8.69. The firm has a market cap of $324.41 million, a P/E ratio of -6.97 and a beta of 2.84. The company has a quick ratio of 1.45, a current ratio of 1.85 and a debt-to-equity ratio of 7.56.

Fluidigm (NASDAQ:FLDM) last announced its earnings results on Thursday, November 1st. The medical research company reported ($0.38) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.18) by ($0.20). Fluidigm had a negative return on equity of 86.00% and a negative net margin of 50.46%. The business had revenue of $28.96 million for the quarter, compared to analyst estimates of $27.50 million. As a group, equities research analysts predict that Fluidigm will post -0.99 EPS for the current year.

In other Fluidigm news, insider Levin Capital Strategies, L.P. bought 9,962 shares of Fluidigm stock in a transaction that occurred on Friday, October 26th. The stock was acquired at an average price of $7.20 per share, for a total transaction of $71,726.40. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have purchased 122,180 shares of company stock valued at $910,163 in the last 90 days. 2.20% of the stock is currently owned by corporate insiders.

Hedge funds have recently made changes to their positions in the business. Campbell & CO Investment Adviser LLC acquired a new stake in Fluidigm in the third quarter valued at $117,000. LMR Partners LLP acquired a new stake in Fluidigm in the second quarter valued at $144,000. Wells Fargo & Company MN lifted its stake in Fluidigm by 64.8% in the first quarter. Wells Fargo & Company MN now owns 28,945 shares of the medical research company’s stock valued at $169,000 after acquiring an additional 11,377 shares during the last quarter. Fairpointe Capital LLC acquired a new stake in Fluidigm in the second quarter valued at $238,000. Finally, Los Angeles Capital Management & Equity Research Inc. acquired a new stake in Fluidigm in the second quarter valued at $240,000. Hedge funds and other institutional investors own 96.68% of the company’s stock.

About Fluidigm

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system.

See Also: Fundamental Analysis and Choosing Stocks

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.